Evgenia I. Markelova

Evgenia I. Markelova

Auto-generated profile, based on publicly available information

Evgenia I. Markelova

V.A. Nasonova Research Institute of Rheumatology

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2019 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
DNDiana S. Novikova
Diana S. Novikova
HUHelen V. Udachkina
Helen V. Udachkina
EMEugenia I. Markelova
Eugenia I. Markelova
IKIrina G. Kirillova
Irina G. Kirillova
AMAnna S. Misiyuk
Anna S. Misiyuk
TVTatyana Popkova V.
Tatyana Popkova V.

27 October 2017 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
HUHelen V. Udachkina
Helen V. Udachkina
DNDiana S. Novikova
Diana S. Novikova
TVTatyana Popkova V.
Tatyana Popkova V.
IKIrina G. Kirillova
Irina G. Kirillova
EMEvgenia I. Markelova
Evgenia I. Markelova
ENEugeniy L. Nasonov
Eugeniy L. Nasonov

20 February 2023 in Life
Verified
Journal Article
Open access
PDF file
ASAlexander Stepanov
Alexander Stepanov
Kristina MalsagovaKristina Malsagova
Kristina Malsagova
AKArthur Kopylov
Arthur Kopylov
VRVladimir Rudnev
Vladimir Rudnev
DKDmitry E. Karateev
Dmitry E. Karateev
AKAnna Kaysheva
Anna Kaysheva
Reduction in tumor necrosis factor (αTNF) and interleukin-6 (IL-6) activities is a widely utilized strategy for the treatment of rheumatoid arthritis (RA) with a high success rate. Despite both schemes targeting the deprivation of inflammatory reactions caused by the excessive activity of cytokines, their mechanisms of action and the final output are still unequal. This was a comparative longitudinal study that lasted for 24 weeks and aimed to find the answer to why the two schemes of therapy can pass out of proportion in attitude of their efficiency. What are the differences in metabolic and proteomic responses among patients who were being treated by either the anti-TNF or anti-IL-6 strategy? We found increased levels of immunoglobulins A and G (more than 2-fold in anti-IL-6 and more than 4-5-fold in anti-TNF groups) at the final stage (24 weeks) of monitoring but the most profound increase was determined for µ-chains of immunoglobulins in both groups of study. Metabolomic changes displayed main alterations with regard to arginine metabolism and collagen maintenance, where arginine increased 8.86-fold (p < 0.001) in anti-TNF and 5.71-fold (p < 0.05) in anti-IL-6 groups but patients treated by the anti-TNF scheme suffered a higher depletion of arginine before the start of therapy. Some indicators of matrix and bone tissue degradation also increased 4-hydroxyproline (4-HP) more than 6-fold (p < 0.001) in anti-TNF and more than 2-fold (p < 0.05) in the anti-IL-6 group, but the growth dynamics in the anti-IL6 group was delayed (gradually raised at week 24) compared to the anti-TNF group (raised at week 12) following a smooth reduction. The ELISA analysis of IL-6 and TNFα concentration in the study population supported proteomic and metabolomic data. A positive correlation between ΔCDAI and ΔDAS28 indicators and ESR and CRP was established for the majority of patients after 24 weeks of treatment where ESR and CRP reduced by 20% and 40% finally, respectively. A regression model using the Forest Plot was estimated to elucidate the impact of the most significant clinical, biochemical, and anthropometric indicators for the evaluation of differences between considered anti-TNF and anti-IL-6 schemes of therapy.

11 May 2018 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
HUHelen V. Udachkina
Helen V. Udachkina
DNDiana S. Novikova
Diana S. Novikova
TVTatyana Popkova V.
Tatyana Popkova V.
IKIrina G. Kirillova
Irina G. Kirillova
EMEvgenia I. Markelova
Evgenia I. Markelova

3 March 2021 in Rheumatology Science and Practice
Verified
Journal Article
Open access
PDF file
EGElena Gerasimova
Elena Gerasimova
TVTatyana Popkova V.
Tatyana Popkova V.
AMA. V. Martynova
A. V. Martynova
IKI. G. Kirillova
I. G. Kirillova
EME. I. Markelova
E. I. Markelova
ENE. L. Nasonov
E. L. Nasonov
The effect of an inhibitor of interleukin-6 (IL-6) receptors on the state of the cardiovascular system in patients with rheumatoid arthritis remains poorly understood.Objective: to study the effect of therapy with an inhibitor of IL-6 receptors, tocilizumab (TCZ), on the dynamics of modifiable risk factors, total cardiovascular risk, and structural changes in the carotid arteries in patients with rheumatoid arthritis during a 12-month follow-up period.Material and methods. The study included 40 patients with active rheumatoid arthritis (33 women and 7 men) with ineffectiveness and/or intolerance to basic anti-inflammatory drugs (DMARDs); the median age was 55 (49; 64) years, the duration of the disease – 102 (48; 162) months; DAS28 – 6.2 (5.5; 6.7) points; all patients were seropositive for rheumatoid factor, 80% – for antibodies to cyclic citrullinated peptide. Patients received TCZ 8 mg/kg therapy every 4 weeks: 52% received TCZ monotherapy, 48% received combined TCZ therapy with DMARDs. All patients underwent an assessment of traditional risk factors, the total cardiovascular risk was calculated using the mSCORE, and atherosclerotic vascular damage was assessed by the detection of atherosclerotic plaques.Results. After 12 months of TCZ therapy, a decrease in disease activity was noted: remission was observed in 25 patients (64%) with rheumatoid arthritis, low disease activity – in 12 (31%); DAS28, HAQ, CRP and ESR concentrations decreased significantly. А high frequency of traditional risk factors was found in rheumatoid arthritis patients: dyslipidemia – 67%, arterial hypertension – 65%, overweight – 55%, burdened heredity for cardiovascular diseases (CVD) – 35%, smoking – 15%. Every third patient had a combination of three or more traditional risk factors. After 12 months of TCZ therapy, the frequency of traditional risk factors did not significantly change, there was an increase in BMI by 2%, an increase in the concentration of HDL-C in serum by 27%, a decrease in the atherogenic index by 28% (p<0.01). Moreover, an increase in the level of HDL-C by the finish was found in patients regardless of statin therapy. Changes in the concentration of other lipids during the observation, including during therapy with statins, were not observed. A negative correlation the dynamics of the levels of ∆HS and ∆CRP (R=−0.37; p<0.05), ∆HS of LDL and ∆CRP (R=−0.42; p<0.01) was found. A very high cardiovascular risk according to the SCORE scale was determined in 78% of patients, moderate – in 2%, and low – in 20% of patients. The distribution of patients by mSCORE value and level of cardiovascular risk were not documented after 12 months of TCZ therapy. No significant structural changes in carotid arteries in rheumatoid arthritis patients were revealed by the end of 12 months of TCZ therapy.Conclusion. After 12 months of TCZ therapy resulted in decreased rheumatoid arthritis activity, increased the level of HDL-C, atherogenic index, BMI; the frequency of traditional risk factors and the total cardiovascular risk did not change. Despite the very high risk of developing CVD associated with the inflammatory activity of rheumatoid arthritis, the accumulation of traditional risk factors and their combination, subclinical atherosclerotic vascular lesions, no significant structural changes in the carotid arteries were found in rheumatoid arthritis patients on TCZ therapy. Insufficient effectiveness of statin therapy was revealed.

1 January 2016 in Rheumatology Science and Practice
Verified
Journal Article
Open access
PDF file
EME. I. Markelova
E. I. Markelova
TKT. V. Korotaeva
T. V. Korotaeva
DND. S. Novikova
D. S. Novikova
ELE. Yu. Loginova
E. Yu. Loginova
SGS. I. Glukhova
S. I. Glukhova
РАСПРОСТРАНЕННОСТЬ МЕТАБОЛИЧЕСКОГО СИНДРОМА У БОЛЬНЫХ ПСОРИАТИЧЕСКИМ АРИТРИТОМ: ЕГО СВЯЗЬ С ВОСПАЛЕНИЕМ И СУБКЛИНИЧЕСКИМ АТЕРОСКЛЕРОЗОМ